Vectus Biosystems

Vectus Biosystems ROCE

The Return on Capital Employed (ROCE) of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is -59.01 %. In the previous year, Return on Capital Employed (ROCE) was 657.68 % — a change of -108.97% (lower).

ROCE

-59.01 %

YoY

-108.97%

Last updated:

In 2026, Vectus Biosystems's return on capital employed (ROCE) was -59.01 %, a -108.97% increase from the 657.68 % ROCE in the previous year.

The Vectus Biosystems ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
63.63 AUD
Jan 1, 2020
39.69 AUD
Jan 1, 2021
128.42 AUD
Jan 1, 2022
74.64 AUD
Jan 1, 2023
-91.85 AUD
Jan 1, 2024
-152.76 AUD
Jan 1, 2025
657.68 AUD
Jan 1, 2026
-59.01 AUD
The Vectus Biosystems ROCE history
YEARROCEYoY
-59.01 %-108.97%
657.68 %-530.53%
-152.76 %+66.32%
-91.85 %-223.05%
74.64 %-41.88%
128.42 %+223.56%
39.69 %-37.62%
63.63 %-64.06%
177.04 %-104.28%
-4,131.83 %+3,750.73%
-107.30 %+400.28%
-21.45 %-99.19%
-2,659.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Vectus Biosystems's Return on Capital Employed (ROCE)

Vectus Biosystems's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Vectus Biosystems's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Vectus Biosystems's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Vectus Biosystems’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Vectus Biosystems stock

Return on Capital Employed (ROCE) of Vectus Biosystems is -59.01 % in 2026.

Return on Capital Employed (ROCE) of Vectus Biosystems changed from 657.68 % to -59.01 %, representing a -108.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Vectus Biosystems

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Vectus Biosystems